Peptide and Small Molecule Inhibitors Targeting Myeloid Cell Leukemia 1 (Mcl-1) as Novel Antitumor Agents

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Myeloid cell leukemia 1 (Mcl-1) is an anti-apoptotic protein crucial for intrinsic apoptosis pathway regulation.
• Mcl-1 overexpression is associated with cancer progression and therapeutic resistance.
• Targeting Mcl-1 presents a potential strategy for novel cancer treatments.

Purpose of the Study:

• To review recent advancements in the development of Mcl-1 inhibitors.
• To categorize and summarize the biological activities of various small molecule and peptide Mcl-1 inhibitors.

Main Methods:

• Literature review of small molecule and peptide inhibitors targeting Mcl-1.
• Categorization of inhibitors based on chemical structure (e.g., gossypol, marinopyrrole, indole derivatives).
• Summary of reported biological activities and therapeutic potential.

Main Results:

• Several classes of Mcl-1 inhibitors have been identified, including peptide inhibitors, gossypol derivatives, marinopyrrole derivatives, S1 derivatives, indole derivatives, and quinoline derivatives.
• Specific inhibitors like S63845, AZD5991, and AMG176 demonstrate significant biological activity.
• Challenges remain in achieving high selectivity for Mcl-1 inhibitors.

Conclusions:

• Mcl-1 is a validated therapeutic target in oncology.
• Small molecule inhibitors of Mcl-1 represent a promising avenue for cancer therapy development.
• Continued research into selective Mcl-1 inhibition is warranted.